Meta-Flux and Mercury Bio have entered a strategic collaboration to apply disease-scale simulation to Mercury Bio's neurodegeneration programmes. The partnership pairs Mercury Bio's work on delivering large-molecule therapeutics to the brain with our mechanistic, in silico models of disease biology, with the aim of mapping how neuronal pathways shift in Parkinson's and Alzheimer's disease before costly experimental and clinical work begins.
For a company building the intelligence layer to simulate disease, this is a natural fit. Delivery and biology are inseparable: a therapeutic that crosses the blood-brain barrier still has to act on the right mechanism, in the right cells, at the right point in the disease. Modelling that mechanism is where we contribute most.
Mercury Bio and the yEV platform
Mercury Bio, based in Santa Fe, New Mexico, develops large-molecule therapeutics for the brain, addressing one of the harder problems in central nervous system medicine: delivery. As the company frames it, progress in Parkinson's and Alzheimer's has been constrained by a chain of obstacles: crossing the blood-brain barrier, entering the neuron, releasing the drug into the cytoplasm while avoiding endosomal degradation, and then acting on the intracellular pathways that drive disease.
The company's platform is built on yeast extracellular vesicles (yEV), which carry proteins, RNA, and other biologics into neurons across the blood-brain barrier. The approach opens a route for cargo that would otherwise be difficult to deliver to the brain, and it makes the choice of what to deliver, and against which mechanism, a decision worth getting right early.
What Meta-Flux contributes
Our role is to model the disease biology that Mercury Bio's therapeutics are meant to act on. We combine multi-omic data with systems-biology modelling to build mechanistic, in silico representations of neurodegeneration, so that predictions about how a perturbation propagates through neuronal pathways trace back to real biological mechanism rather than correlation alone.
Applied to Mercury Bio's programmes, this maps how pathways shift as Parkinson's and Alzheimer's disease progress, and simulates how intervening at a given node changes system behaviour. In practice, that sharpens three decisions that shape a programme: target selection, pathway prioritisation, and biomarker strategy. Working these through in silico narrows the field ahead of the wet-lab and clinical work that consumes most of a programme's time and cost.
Why this matters for neurodegeneration
Neurodegeneration is unforgiving territory for drug development. Disease mechanisms are entangled, patient populations are heterogeneous, and the gap between a plausible target and a therapy that changes the disease course is wide. A delivery platform that can reach neurons is a significant capability; combined with a clear, mechanistic view of which pathways to engage and how to read the response, it becomes a more directed one.
By simulating disease biology ahead of the bench, the collaboration is intended to reduce the number of expensive dead ends and to ground each candidate decision in a traceable account of the underlying mechanism. That is the work Meta-Flux was built to do.
“This partnership allows us to evaluate disease mechanisms and therapeutic hypotheses in a context that has historically been inaccessible.”
Lee Sherlock, CEO, Meta-Flux